
Home » AASTROM 3Q LOSS WIDENS 37 PERCENT
AASTROM 3Q LOSS WIDENS 37 PERCENT
May 10, 2006
Aastrom Biosciences Inc., which develops stem cell-based tissue-regeneration products, said Wednesday its third-quarter loss widened 37 percent as expenses increased, and announced it can now start
making products at its German plant.
The Houston Chronicle
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
10Mar
-
16Mar
-
18Mar
-
23Mar
-
30Mar
-
06Apr